; (3) enabling and promoting tuberculosis research to develop innovative new diagnostics, drug therapies, and vaccines, and program-based operational research; and (4) funding for the Stop Tuberculosis Partnership’s Global Drug Facility the Stop Tuberculosis Partnership, and the Global Alliance for Tuberculosis Drug Development. (g) Assistance for the World Health Organization and the Stop Tuberculosis Partnership In carrying out this section, the President, acting through the Administrator of the United States Agency for International Development, is authorized to provide increased resources to the World Health Organization and the Stop Tuberculosis Partnership to improve the capacity of countries with high rates of tuberculosis and other affected countries to implement the Stop Tuberculosis Strategy and specific strategies related to addressing MDR–TB and XDR–TB. (h) Annual report on tuberculosis activities The President shall submit an annual report to Congress that describes the impact of United States foreign assistance on efforts to control tuberculosis, including— (1) the number of people with active tuberculosis and the number with tuberculosis infection diagnosed and treated, including the rate of treatment completion and the number receiving patient support, in countries receiving United States bilateral foreign assistance for tuberculosis control purposes; (2) the number of persons who have been diagnosed and started treatment for MDR–TB and XDR–TB in countries receiving United States bilateral foreign assistance for tuberculosis control programs; (3) a description of the collaboration and coordination of United States anti-tuberculosis efforts with the World Health Organization, the Global Fund, and other major public and private entities